Landos Biopharma Raises $60 Million, Starts Phase 2 Trials Of BT-11

Landos Biopharma, the Blacksburg, Virginia clinical-stage biopharmaceutical company recently raised $60 million in a round of fundraising. The Series B round was co-led by RTW Investments and Perceptive Advisors. New investors Osage University Partners and PBM Capital also participated in the fundraising. Proceeds from the funding will go to support Landos’ Phase 2 global clinical trials for BT-11 which is an oral, gut-restricted small molecule therapeutic that targets a novel pathway called Lanthionine Synthetase C-Like 2 (LANCL2)...